Review article
An approach to evidence-based therapeutic apheresis
Bruce C. McLeod,
Corresponding Author
Bruce C. McLeod
Rush Medical College and Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois
Rush Medical College and Rush Presbyterian St. Luke's Medical Center, 1753 W. Congress Parkway, Chicago, IL 60612Search for more papers by this authorBruce C. McLeod,
Corresponding Author
Bruce C. McLeod
Rush Medical College and Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois
Rush Medical College and Rush Presbyterian St. Luke's Medical Center, 1753 W. Congress Parkway, Chicago, IL 60612Search for more papers by this authorAbstract
This review is derived from a memorial lecture honoring Dr. Francis Morrison, a former President of the American Society For Apheresis (ASFA). The author had numerous professional contacts with Dr. Morrison through ASFA in the early 1990s, having served with him on the Board of Directors and followed him as President, and also came to know him well on a personal level. Professionally, Dr. Morrison stood out as a courtly gentleman with a marvelous baritone voice whose ability to facilitate organization contributed to a growing sense of dignity and purpose in the affairs of the society. On the personal side, however, there wasn't an ounce of pretension in him. He was accessible and down-to-earth; a genuine character with an active and appealing sense of humor. Not surprisingly, he seemed to have a wealth of insight and “common sense,” and since the topic of this study is a kind of common sense approach to assessing the effectiveness of therapeutic apheresis, it seems a fitting way to honor his memory. J. Clin. Apheresis 17:124–132, 2002. © 2002 Wiley-Liss, Inc.
REFERENCES
- 1 Morens DM. Death of a president. N Engl J Med 1999; 341: 1845–1849.
- 2 Weinstein R. Basic principles of blood exchange. In: BC McLeod, TH Price, MJ Drew, editors. Apheresis: principles and practice. Bethesda: AABB Press; 1997. p 263–296.
- 3 Goodman SN. Toward evidence-based medical statistics. 1: the P value follacy. Ann Int Med 1999; 130: 995–1004.
- 4 Goodman SN. Toward evidence-based medical statistics. 2: the Bayes factor. Ann Int Med 1999; 130: 1005–1013.
- 5 Cuttner J, Holland J, Norton L, et al. Therapeutic leukaphersis for hyperleukocytosis in acute myelocytic leukemia. Med Pediat Oncol 1983; 11: 76–78.
- 6 Porcu P, Danielson CF, Orazi A, et al. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol 1997; 98: 433–436.
- 7 Cook SD, Dowling PC, Murray MR, Whitaker JN. Circulating demyelinating factors in acute idiopathic polyneuropathy. Arch Neurol 1971; 24: 136–144.
- 8 Saida T, Saida K, Lisak RP, Brown MJ, Silverberg DH, Asbury AK. In vivo demyelinating activity of sera from patients with Guillain-Barré syndrome. Ann Neurol 1985; 11: 69–75.
- 9 Guillain-Barré Syndrome Study Group. TPE and acute Guillain-Barré syndrome. Neurology 1985; 35: 1096–1104.
- 10 Osterman PG, Lundemo G, Pirskanen R, et al. Beneficial effects of TPE in acute inflammatory polyradiculoneuropathy. Lancet 1984; 2: 1296–1299.
- 11 French Cooperative Group on TPE in Guillain-Barré syndrome. Efficiency of TPE in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22: 753–761.
- 12 Koski CL, Gratz E, Sutherlan J, et al. Clinical correlation with anti-peripheral myelin antibodies in Guillain-Barré syndrome. Ann Neurol 1986; 19: 573–577.
- 13 McKhann GM, Cornblath DR, Griffen JW, et al. Acute motor axonal neuropathy: A frequent cause of flaccid paralysis in China. Ann Neurol 1993; 33: 333–342.
- 14 Rees JH, Gregson NA, Hughes RA. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995; 38: 809–816.
- 15 Rees JH, Soudain SE, Gregson NA, Hughes RAC. Campylobacter jejuni; infection and Guillain-Barré syndrome. N Engl J Med 1995; 333: 1374–1379.
- 16 Vriesendorp FJ, Mayer RF, Koski CL. Kinetics of anti-peripheral nerve myelin antibody in patients with in Guillain-Barré syndrome treated and not treated with TPE. Arch Neurol 1991; 48: 858–861.
- 17 TPE/Sandoglobulin in Guillain-Barré Syndrome Trial Group. Randomised trial of TPE, intravenous immunoglobulin, and combined treatments in in Guillain-Barré syndrome. Lancet 1997; 349: 225–230.
- 18 Lindstrom JM, Seybold ME, Lennon VA, et al. Antibody to acetylcholine receptor in myasthenia gravis. Neurology 1976; 26: 1054–1059.
- 19 Dau PC, Lindstrom JM, Cassel CK, et al. TPE and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 1997; 297: 1134–1140.
- 20 Dau PC. TPE therapy in myasthenia gravis. Muscle Nerve 1980; 3: 468–482.
- 21 Gajdos P, Chevret S, Clair B, Tranchant C, Chastrang C. Clinical trial of TPE and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997; 41: 789–796.
- 22 Reeves WH, Satoh M, Jingson W, Chou C-H, Ajmani AK. Systemic lupus erythematosus: antibodies to DNA, DNA-binding proteins and histones. Rheum Dis Clin North Am 1994; 20: 1–28.
- 23 Jones JV, Robinson MF, Parciany RK, Layter LF, McLeod B. Therapeutic plasmapheresis in systemic lupus erythematosus: effect on immune complexes and antibodies to DNA. Arthritis Rheum 1981; 24: 1113–1120.
- 24 Jones JV, Cumming RH, Bucknall RC, Asplin CM. TPE in the management of acute sytemic lupus erythematosus? Lancet 1976; 1: 700–711.
- 25 Jones JV, Cumming RH, Bacon PA, et al. Evidence for a therapeutic effect of TPE in patients with systemic lupus erythematosus. Q J Med 1979; 48: 555–576.
- 26 Lewis EJ, Hunsicker LG, Lan SP, et al. A controlled trial of TPE therapy in severe lupus nephritis. N Engl J Med 1992; 326: 1371–1379.
- 27 Euler HH, Schwab UM, Schroeder JO, Hasford J. The lupus TPE study group: rationale and updated interim report. Artif Organs 1996; 20: 356–359.
- 28 Schroeder JO, Schwab U, Zennet R, et al. TPE and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. Preliminary results of the LPSG Trial. Arthrit Rheum 1997; 40: S325.
- 29 Atkinson JP. Complement deficiency: predisposing factor to autoimmune syndromes. Clin Exp Rheumatol 1989; 7 (Suppl 3): S95–101.
- 30 Terman DS, Garcia-Rinaldi R, Dannemann B, et al. Specific suppression of antibody rebound after extracorporeal immunoadsorption. Clin Exp Immunol 1978; 34: 32–41.
- 31 Derlsem R.H.W.M., Schuurman H.J., Gmelig Meyling F.H.J., Struvyenberg A, Kater L. Rebound and overshoot after TPE in humans. J Lab Clin Med 1989; 104: 35–43.
- 32 Junghans RP. IgG biosynthesis: No “immunoregulatory feedback.” Blood 1997; 90: 3815–3818.
- 33
Weinstein R.
Therapeutic apheresis in neurological disorders.
J Clin Apheresis
2000;
15:
74–128.
10.1002/(SICI)1098-1101(2000)15:1/2<74::AID-JCA6>3.0.CO;2-O CAS PubMed Web of Science® Google Scholar
- 34 Weiner HL, Dau P, Khatri BO, et al. Double-blind study of true versus sham TPE in patients being treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989; 39: 1143–1149.
- 35 Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and TPE in progressive multiple sclerosis. Lancet 1991; 337: 441–446.
- 36 Assessment of TPE. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1996; 47: 840–843.
- 37 Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of TPE in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878–886.
- 38
Winters JL,
Pineda AA,
McLeod BC,
Grima KM.
Therapeutic apheresis in renal and metabolic diseases.
J Clin Apheresis
2000;
15:
53–73.
10.1002/(SICI)1098-1101(2000)15:1/2<53::AID-JCA5>3.0.CO;2-W CAS PubMed Web of Science® Google Scholar
- 39 Soulillou JP, Guyot C, Guimbretiere J, et al. TPE in early kidney graft rejection associated with anti-donor antibodies. Nephron 1983; 35: 158–162.
- 40 Allen NH, Ayer P, Geoghegan T, Harris K, Lee HA, Slapak M. TPE in acute renal allograft rejection: a controlled trial. Transplantation 1983; 35: 425–428.
- 41 Kirubakaran MG, Disney APS, Norman J, Pugsley DJ, Mathew TH. A controlled trial of TPE in the treatment of renal allograft rejection. Transplantation 1981; 35: 164–165.
- 42 Blake P, Sutton D, Cardella C. TPE in acute renal transplant rejction. Prog Clin Biol Res 1990; 337: 249–252.
- 43 Bonomini V, Vangelista A, Frasca GM, DiFelice A, Liviano-D'Arcangelo G. Effects of TPE in renal transplant rejection: a controlled study. Trans Am Soc Artif Intern Organs 1985; 31: 698–700.
- 44 Crespo M, Pascual M, Tolkoff-Rubin N, et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 652–658.
- 45 Winkel E, DiSesa VK. Costanzo MR. Advances in heart transplantation. Disease-a-Month 1999; 45: 63–87.
- 46 Kirlin JK, Bourge RC, McGiffin DC. Recurrent or persistent allograft rejection: therapeutic options and recommendations. Transplant Proc 1997; 29: 40S–44S.
- 47 Heroux AL, Costanzo-Nordin MR, Radvany R, et al. The enigman of acute allograft dysfunction without cellular rejection: role of humoral immunity. J Heart Lung Transplant 1993: 12: S91 (abstract).
- 48 Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. N Engl J Med 1998; 339: 1744–1751.
- 49 Goronzy J, Weyland C. Rheumatoid arthritis. In: Klippel, editor. Primer on the rheumatic diseases. Atlanta: Arthritis Foundation; 1997. p 155–161.
- 50
Koo AP.
Therapeutic apheresis in autoimmune and rheumatic diseases.
J Clin Apheresis
2000;
15:
18–27.
10.1002/(SICI)1098-1101(2000)15:1/2<18::AID-JCA3>3.0.CO;2-R CAS PubMed Web of Science® Google Scholar
- 51 Felson DT, La Valley MP, Baldassare AR, et al. The ProSorba column for the treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham controlled trial. Arthrit Rheum 1999; 42: 21: 2153–2159.
- 52
Grima KM.
Therapeutic apheresis in hematological and oncological diseases.
J Clin Apheresis
2000;
15:
28–52.
10.1002/(SICI)1098-1101(2000)15:1/2<28::AID-JCA4>3.0.CO;2-N CAS PubMed Web of Science® Google Scholar
- 53 Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578–1584.
- 54 Tsai H-M, Lian EC-Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J. Med 1998; 339: 1585–1594.
Citing Literature
